Zanubrutinib in Patients With Relapsed/Refractory Waldenström Macroglobulinemia
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients With Relapsed/Refractory Waldenström Macroglobulinemia
Clin. Cancer Res 2021 Jul 12;[EPub Ahead of Print], G An, D Zhou, S Cheng, KS Zhou, J Li, J Zhou, L Xie, J Jin, LY Zhong, L Yan, H Guo, C Du, J Zhong, Y Yu, B Wu, L QiuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.